Which has higher earnings & valuation, NEO or BILI?

Bilibili has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Bilibili, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeoGenomics $727.33M 2.55 -$108.03M -$0.77 N/A Bilibili $4.34B 1.76 $170.67M $0.45 40.91

Is NEO or BILI more profitable?

Bilibili has a net margin of 4.58% compared to NeoGenomics' net margin of -13.30%. Bilibili's return on equity of 10.81% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets NeoGenomics -13.30% -2.80% -1.72% Bilibili 4.58% 10.81% 4.04%

Does the media refer more to NEO or BILI?

In the previous week, NeoGenomics had 1 more articles in the media than Bilibili. MarketBeat recorded 4 mentions for NeoGenomics and 3 mentions for Bilibili. NeoGenomics' average media sentiment score of 0.66 beat Bilibili's score of 0.43 indicating that NeoGenomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bilibili 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, NEO or ZG?

Zillow Group has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Zillow Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeoGenomics $727.33M 2.55 -$108.03M -$0.77 N/A Zillow Group $2.58B 2.91 $23M $0.25 131.36

Does the media refer more to NEO or ZG?

In the previous week, Zillow Group had 9 more articles in the media than NeoGenomics. MarketBeat recorded 13 mentions for Zillow Group and 4 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.66 beat Zillow Group's score of 0.00 indicating that NeoGenomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zillow Group 0 Very Positive mention(s) 0 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, NEO or HNGE?

NeoGenomics has higher revenue and earnings than Hinge Health. NeoGenomics is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeoGenomics $727.33M 2.55 -$108.03M -$0.77 N/A Hinge Health $587.86M 11.52 -$528.26M -$12.34 N/A

Is NEO or HNGE more profitable?

NeoGenomics has a net margin of -13.30% compared to Hinge Health's net margin of -78.95%. NeoGenomics' return on equity of -2.80% beat Hinge Health's return on equity. Company Net Margins Return on Equity Return on Assets NeoGenomics -13.30% -2.80% -1.72% Hinge Health -78.95% -310.62% -71.08%

Does the media refer more to NEO or HNGE?

In the previous week, NeoGenomics had 1 more articles in the media than Hinge Health. MarketBeat recorded 4 mentions for NeoGenomics and 3 mentions for Hinge Health. Hinge Health's average media sentiment score of 1.20 beat NeoGenomics' score of 0.66 indicating that Hinge Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hinge Health 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend QMMM or NEO?

NeoGenomics has a consensus target price of $13.86, suggesting a potential downside of 2.69%. Given NeoGenomics' stronger consensus rating and higher possible upside, analysts clearly believe NeoGenomics is more favorable than QMMM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score QMMM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NeoGenomics 1 Sell rating(s) 5 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.42

Which has preferable earnings & valuation, QMMM or NEO?

QMMM has higher earnings, but lower revenue than NeoGenomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio QMMM $2.70M 2,529.95 -$1.58M N/A N/A NeoGenomics $727.33M 2.55 -$108.03M -$0.77 N/A

Is QMMM or NEO more profitable?

QMMM has a net margin of 0.00% compared to NeoGenomics' net margin of -13.30%. QMMM's return on equity of 0.00% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets QMMM N/A N/A N/A NeoGenomics -13.30% -2.80% -1.72%

Which has better earnings and valuation, NEO or SEZL?

Sezzle has lower revenue, but higher earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Sezzle, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeoGenomics $727.33M 2.55 -$108.03M -$0.77 N/A Sezzle $450.28M 12.83 $133.13M $4.21 40.80

Is NEO or SEZL more profitable?

Sezzle has a net margin of 30.83% compared to NeoGenomics' net margin of -13.30%. Sezzle's return on equity of 87.46% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets NeoGenomics -13.30% -2.80% -1.72% Sezzle 30.83% 87.46% 36.29%

Does the media refer more to NEO or SEZL?

In the previous week, Sezzle had 6 more articles in the media than NeoGenomics. MarketBeat recorded 10 mentions for Sezzle and 4 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.66 beat Sezzle's score of 0.17 indicating that NeoGenomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sezzle 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

NeoGenomics (NEO) Competitors

$14.24 -0.37 (-2.53%)

Closing price 04:00 PM Eastern

Extended Trading

$14.47 +0.23 (+1.61%)

As of 07:57 PM Eastern

Compare

NEO vs. BILI, ZG, HNGE, QMMM, and SEZL

Should you buy NeoGenomics stock or one of its competitors? MarketBeat compares NeoGenomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeoGenomics include Bilibili (BILI), Zillow Group (ZG), Hinge Health (HNGE), QMMM (QMMM), and Sezzle (SEZL). These companies are all part of the "business services" industry.

How does NeoGenomics compare to Bilibili?

NeoGenomics (NASDAQ:NEO) and Bilibili (NASDAQ:BILI) are both business services companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

98.5% of NeoGenomics shares are held by institutional investors. Comparatively, 16.1% of Bilibili shares are held by institutional investors. 1.1% of NeoGenomics shares are held by insiders. Comparatively, 22.2% of Bilibili shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

NeoGenomics presently has a consensus price target of $13.86, suggesting a potential downside of 2.69%. Bilibili has a consensus price target of $30.78, suggesting a potential upside of 67.18%. Given Bilibili's stronger consensus rating and higher possible upside, analysts clearly believe Bilibili is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42
Bilibili	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, NeoGenomics had 1 more articles in the media than Bilibili. MarketBeat recorded 4 mentions for NeoGenomics and 3 mentions for Bilibili. NeoGenomics' average media sentiment score of 0.66 beat Bilibili's score of 0.43 indicating that NeoGenomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bilibili	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bilibili has a net margin of 4.58% compared to NeoGenomics' net margin of -13.30%. Bilibili's return on equity of 10.81% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-13.30%	-2.80%	-1.72%
Bilibili	4.58%	10.81%	4.04%

NeoGenomics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market. Comparatively, Bilibili has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

Bilibili has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Bilibili, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	2.55	-$108.03M	-$0.77	N/A
Bilibili	$4.34B	1.76	$170.67M	$0.45	40.91

Summary

Bilibili beats NeoGenomics on 11 of the 16 factors compared between the two stocks.

How does NeoGenomics compare to Zillow Group?

NeoGenomics (NASDAQ:NEO) and Zillow Group (NASDAQ:ZG) are both business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, Zillow Group had 9 more articles in the media than NeoGenomics. MarketBeat recorded 13 mentions for Zillow Group and 4 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.66 beat Zillow Group's score of 0.00 indicating that NeoGenomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zillow Group	0 Very Positive mention(s)	0 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zillow Group has a net margin of 2.27% compared to NeoGenomics' net margin of -13.30%. Zillow Group's return on equity of 1.41% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-13.30%	-2.80%	-1.72%
Zillow Group	2.27%	1.41%	1.22%

Zillow Group has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Zillow Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	2.55	-$108.03M	-$0.77	N/A
Zillow Group	$2.58B	2.91	$23M	$0.25	131.36

NeoGenomics currently has a consensus target price of $13.86, suggesting a potential downside of 2.69%. Zillow Group has a consensus target price of $69.48, suggesting a potential upside of 111.56%. Given Zillow Group's stronger consensus rating and higher possible upside, analysts plainly believe Zillow Group is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42
Zillow Group	1 Sell rating(s)	11 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.54

98.5% of NeoGenomics shares are held by institutional investors. Comparatively, 20.3% of Zillow Group shares are held by institutional investors. 1.1% of NeoGenomics shares are held by insiders. Comparatively, 29.9% of Zillow Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

NeoGenomics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Zillow Group has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market.

Summary

Zillow Group beats NeoGenomics on 15 of the 17 factors compared between the two stocks.

How does NeoGenomics compare to Hinge Health?

NeoGenomics (NASDAQ:NEO) and Hinge Health (NYSE:HNGE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

In the previous week, NeoGenomics had 1 more articles in the media than Hinge Health. MarketBeat recorded 4 mentions for NeoGenomics and 3 mentions for Hinge Health. Hinge Health's average media sentiment score of 1.20 beat NeoGenomics' score of 0.66 indicating that Hinge Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hinge Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeoGenomics has a net margin of -13.30% compared to Hinge Health's net margin of -78.95%. NeoGenomics' return on equity of -2.80% beat Hinge Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-13.30%	-2.80%	-1.72%
Hinge Health	-78.95%	-310.62%	-71.08%

NeoGenomics has higher revenue and earnings than Hinge Health. NeoGenomics is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	2.55	-$108.03M	-$0.77	N/A
Hinge Health	$587.86M	11.52	-$528.26M	-$12.34	N/A

98.5% of NeoGenomics shares are held by institutional investors. 1.1% of NeoGenomics shares are held by company insiders. Comparatively, 18.9% of Hinge Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NeoGenomics presently has a consensus price target of $13.86, suggesting a potential downside of 2.69%. Hinge Health has a consensus price target of $82.67, suggesting a potential downside of 5.55%. Given NeoGenomics' higher probable upside, equities research analysts clearly believe NeoGenomics is more favorable than Hinge Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42
Hinge Health	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.95

NeoGenomics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market. Comparatively, Hinge Health has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Summary

NeoGenomics beats Hinge Health on 10 of the 17 factors compared between the two stocks.

How does NeoGenomics compare to QMMM?

QMMM (NASDAQ:QMMM) and NeoGenomics (NASDAQ:NEO) are both business services companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

QMMM has a beta of 14.57, indicating that its stock price is 1,357% more volatile than the broader market. Comparatively, NeoGenomics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

QMMM has higher earnings, but lower revenue than NeoGenomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QMMM	$2.70M	2,529.95	-$1.58M	N/A	N/A
NeoGenomics	$727.33M	2.55	-$108.03M	-$0.77	N/A

98.5% of NeoGenomics shares are held by institutional investors. 1.1% of NeoGenomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, NeoGenomics had 4 more articles in the media than QMMM. MarketBeat recorded 4 mentions for NeoGenomics and 0 mentions for QMMM. NeoGenomics' average media sentiment score of 0.66 beat QMMM's score of 0.00 indicating that NeoGenomics is being referred to more favorably in the news media.

Company	Overall Sentiment
QMMM	Neutral
NeoGenomics	Positive

QMMM has a net margin of 0.00% compared to NeoGenomics' net margin of -13.30%. QMMM's return on equity of 0.00% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QMMM	N/A	N/A	N/A
NeoGenomics	-13.30%	-2.80%	-1.72%

NeoGenomics has a consensus target price of $13.86, suggesting a potential downside of 2.69%. Given NeoGenomics' stronger consensus rating and higher possible upside, analysts clearly believe NeoGenomics is more favorable than QMMM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QMMM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NeoGenomics	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42

Summary

NeoGenomics beats QMMM on 8 of the 14 factors compared between the two stocks.

How does NeoGenomics compare to Sezzle?

NeoGenomics (NASDAQ:NEO) and Sezzle (NASDAQ:SEZL) are both business services companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Sezzle has lower revenue, but higher earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Sezzle, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	2.55	-$108.03M	-$0.77	N/A
Sezzle	$450.28M	12.83	$133.13M	$4.21	40.80

98.5% of NeoGenomics shares are held by institutional investors. Comparatively, 2.0% of Sezzle shares are held by institutional investors. 1.1% of NeoGenomics shares are held by company insiders. Comparatively, 49.5% of Sezzle shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Sezzle had 6 more articles in the media than NeoGenomics. MarketBeat recorded 10 mentions for Sezzle and 4 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.66 beat Sezzle's score of 0.17 indicating that NeoGenomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sezzle	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeoGenomics presently has a consensus price target of $13.86, suggesting a potential downside of 2.69%. Sezzle has a consensus price target of $151.33, suggesting a potential downside of 11.89%. Given NeoGenomics' higher possible upside, equities research analysts plainly believe NeoGenomics is more favorable than Sezzle.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42
Sezzle	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.56

NeoGenomics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market. Comparatively, Sezzle has a beta of 6.7, indicating that its stock price is 570% more volatile than the broader market.

Sezzle has a net margin of 30.83% compared to NeoGenomics' net margin of -13.30%. Sezzle's return on equity of 87.46% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-13.30%	-2.80%	-1.72%
Sezzle	30.83%	87.46%	36.29%

Summary

Sezzle beats NeoGenomics on 12 of the 17 factors compared between the two stocks.

Get NeoGenomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEO vs. The Competition

Export

Metric	NeoGenomics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.90B	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-18.49	20.49	27.10	23.94
Price / Sales	2.55	300.39	517.51	91.95
Price / Cash	43.61	60.31	26.68	47.25
Price / Book	2.20	7.92	10.66	6.14
Net Income	-$108.03M	$23.81M	$3.60B	$331.74M
7 Day Performance	0.92%	-1.27%	-1.51%	-1.72%
1 Month Performance	27.94%	2.56%	1.11%	-1.44%
1 Year Performance	128.21%	42.49%	23.77%	16.97%

NeoGenomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEO NeoGenomics	1.5723 of 5 stars	$14.24 -2.5%	$13.86 -2.7%	+134.1%	$1.90B	$727.33M	N/A	2,500
BILI Bilibili	3.5088 of 5 stars	$17.59 -0.6%	$30.78 +75.0%	-28.4%	$7.34B	$4.34B	39.09	8,423
ZG Zillow Group	4.0919 of 5 stars	$31.94 -0.2%	$69.48 +117.5%	-54.7%	$7.32B	$2.58B	127.76	7,068
HNGE Hinge Health	2.5034 of 5 stars	$90.04 +1.4%	$82.67 -8.2%	+84.5%	$6.87B	$587.86M	N/A	1,437
QMMM QMMM	0.0845 of 5 stars	$119.40 flat	N/A	N/A	$6.83B	$2.70M	N/A	N/A	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEO) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeoGenomics (NEO) Competitors

NEO vs. BILI, ZG, HNGE, QMMM, and SEZL

How does NeoGenomics compare to Bilibili?

Summary

How does NeoGenomics compare to Zillow Group?

Summary

How does NeoGenomics compare to Hinge Health?

Summary

How does NeoGenomics compare to QMMM?

Summary

How does NeoGenomics compare to Sezzle?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEO vs. The Competition

NeoGenomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeoGenomics (NEO) Competitors

NEO vs. BILI, ZG, HNGE, QMMM, and SEZL

How does NeoGenomics compare to Bilibili?

Do insiders & institutionals have more ownership in NEO or BILI?

Do analysts recommend NEO or BILI?

Does the media refer more to NEO or BILI?

Is NEO or BILI more profitable?

Which has more risk & volatility, NEO or BILI?

Which has higher earnings & valuation, NEO or BILI?

Summary

How does NeoGenomics compare to Zillow Group?

Does the media refer more to NEO or ZG?

Is NEO or ZG more profitable?

Which has preferable valuation & earnings, NEO or ZG?

Do analysts recommend NEO or ZG?

Do insiders and institutionals have more ownership in NEO or ZG?

Which has more risk and volatility, NEO or ZG?

Summary

How does NeoGenomics compare to Hinge Health?

Does the media refer more to NEO or HNGE?

Is NEO or HNGE more profitable?

Which has stronger earnings and valuation, NEO or HNGE?

Do insiders & institutionals have more ownership in NEO or HNGE?

Do analysts recommend NEO or HNGE?

Which has more volatility and risk, NEO or HNGE?

Summary

How does NeoGenomics compare to QMMM?

Which has more risk & volatility, QMMM or NEO?

Which has preferable earnings & valuation, QMMM or NEO?

Do institutionals and insiders hold more shares of QMMM or NEO?

Does the media favor QMMM or NEO?

Is QMMM or NEO more profitable?

Do analysts recommend QMMM or NEO?

Summary

How does NeoGenomics compare to Sezzle?

Which has better earnings and valuation, NEO or SEZL?

Do institutionals & insiders have more ownership in NEO or SEZL?

Does the media refer more to NEO or SEZL?

Do analysts rate NEO or SEZL?

Which has more risk & volatility, NEO or SEZL?

Is NEO or SEZL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEO vs. The Competition

NeoGenomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools